BiotechTube

ASN008

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dermatitis, Atopic

Conditions

Dermatitis, Atopic, Pruritus

Trial Timeline

May 3, 2023 → Dec 28, 2023

NCT ID
NCT05870865

About ASN008

ASN008 is a phase 2 stage product being developed by Formation Bio for Dermatitis, Atopic. The current trial status is completed. This product is registered under clinical trial identifier NCT05870865. Target conditions include Dermatitis, Atopic, Pruritus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05870865Phase 2Completed

Competing Products

20 competing products in Dermatitis, Atopic

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
25
LebrikizumabEli LillyPhase 3
77
ENS-002Concerto BiosciencesPhase 1
25
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
52
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaApproved
85
Tacrolimus Ointment 0.1%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77